Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Common Equity (2024 - 2025)

Xilio Therapeutics' Common Equity history spans 2 years, with the latest figure at -$8.1 million for Q3 2025.

  • For Q3 2025, Common Equity fell 138.6% year-over-year to -$8.1 million; the TTM value through Sep 2025 reached -$8.1 million, down 138.6%, while the annual FY2024 figure was $17.6 million, N/A changed from the prior year.
  • Common Equity for Q3 2025 was -$8.1 million at Xilio Therapeutics, down from $7.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $33.4 million in Q2 2024 and bottomed at -$8.1 million in Q3 2025.